

1 **Brain magnetic resonance imaging software to support dementia diagnosis**
2 **in routine clinical practice: a barrier to adoption study in the National**
3 **Health Service (NHS) England**

4 Short title: Brain MRI software to support dementia diagnosis in NHS England

5

6 Ludovica Griffanti^{1,2,3*}¶, Florence Serres⁴¶, Laura Cini^{1,3}, Jessica Walsh^{1,3}, Taylor Hanayik³, Usama
7 Pervaiz³, Stephen Smith³, Heidi Johansen-Berg^{1,3}, James Rose⁴, Mamta Bajre⁴

8

9 ¹ NIHR Oxford Health Biomedical Research Centre, Oxford, UK

10 ² Wellcome Centre for Integrative Neuroimaging, OHBA, Department of Psychiatry, University of
11 Oxford, Oxford, UK

12 ³ Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical
13 Neurosciences, University of Oxford, Oxford, UK

14 ⁴ Health Innovation Oxford and Thames Valley, Health Innovation Oxford and Thames Valley.
15 Magdalen Centre, Oxford Science Park, Oxford, UK

16

17 * Corresponding author

18 E-mail: ludovica.griffanti@psych.ox.ac.uk (LG)

19

20 ¶ These authors contributed equally to this work

21

22 **Abstract**

23 With the rise in numbers of people living with dementia and new disease modifying therapies entering
24 the market, there is increasing need for brain magnetic resonance imaging (MRI) for diagnosis and
25 safety monitoring. The number of scans that need reporting is expected to rapidly grow. Clinical
26 radiology reports are currently largely qualitative and variable in structure and content. By contrast,
27 research software typically uses automated methods to extract quantitative metrics from brain scans.

28 To better understand the unmet clinical need for brain reporting software for dementia we conducted a
29 barrier to adoption study using the Lean Assessment Process (LAP) methodology. We first assessed the
30 role of brain imaging in the diagnostic pathway for people with suspected dementia in the NHS in
31 England. We then explored the views of (neuro)radiologists, neurologists and psychiatrists on the
32 potential benefits and level of acceptance of software to support brain MRI analysis, using the FMRIB
33 software library (FSL) as a technology exemplar.

34 The main perceived utilities of the proposed software were: increased diagnostic confidence; support
35 for delivery of disease modifying therapies; and the possibility to compare individual results with
36 population norms. In addition to assessment of global atrophy, hippocampal atrophy and white matter
37 hyperintensities, additional user requirements included assessment of microbleeds, segmentation of
38 multiple brain structures, clear information about the control population used for reference, and
39 possibility to compare multiple scans. The main barriers to adoption related to the limited availability
40 of 3T MRI scanners in the UK, integration into the clinical workflow, and the need to demonstrate cost-
41 effectiveness. These findings will guide future technical development, clinical validation, and health
42 economic evaluation.

43

44 Introduction

45 In the UK, it is estimated that more than 944,000 people are currently living with dementia, with an
46 associated economic cost forecast at £42 billion to the UK economy in 2024 (1) and predicted to
47 increase to £94 billion by 2040 as the population ages (2)

48 NICE recommends the use of structural imaging, either Computerised Tomography (CT) or Magnetic
49 Resonance Imaging (MRI) in the diagnosis of people with suspected dementia (3). Although CT
50 scanning is widely available, cheaper, and as reliable as MRI in excluding potentially treatable
51 conditions, MRI is more sensitive to detecting subtle changes, to assess vascular pathology, and to aid
52 in differential diagnosis of dementia (4). Subtle brain changes can however be challenging to identify
53 and quantify, as MRI brain scans are currently reviewed visually by a neuroradiologist. Various visual
54 rating scales are available to enable a semi-quantitative assessment, but their impact and inter/intra-
55 rater reliability is variable (5), and they require time and expertise (6). As a result, they have not been
56 widely adopted into routine clinical practice, where the information included in imaging reports remains
57 largely qualitative and of variable quality.

58 The 2021 National Audit for Dementia from the Royal College of Psychiatrists reported an increase in
59 MRI scans from 26% of total neuroimaging scans performed in 2019 to 31.8% in 2021 (7), a figure set
60 to increase dramatically in coming years as the population ages and new disease modifying therapies
61 (DMTs) enter the market. Monoclonal antibodies are emerging DMTs for Alzheimer's disease that
62 require brain MR imaging for eligibility assessment and monitoring for amyloid-related imaging
63 abnormalities (8). Extracting accurate quantitative measurements from MRI scans could aid in
64 differential diagnosis for eligibility screening and longitudinal tracking of disease progression,
65 treatment response and safety from side effects.

66 In contrast to the clinic, measures automatically extracted from brain scans to objectively assess atrophy
67 and vascular damage are widely used in dementia *research*, with a variety of research software tools
68 available (e.g. FSL, FreeSurfer, SPM, AFNI). Additionally, there are multiple commercial products

69 emerging that are regulatory approved for clinical use (9). Despite this, there is limited adoption of
70 dementia neuroimaging tools in clinical settings in UK clinics. Previously reported reasons for
71 (neuro)radiologists not to perform quantitative evaluation in dementia imaging include lack of access
72 to software algorithms and expertise, lack of picture archiving and communication system (PACS)
73 integration, cost, users not comfortable with interpretation and the belief that it would be too time-
74 consuming or user intensive (6). However, studies suggest that providing a quantitative analysis to
75 clinicians improves interrater variability whilst increasing diagnostic confidence, sensitivity, and
76 accuracy for diagnostic interpretation in dementia (10-12).

77 This barrier to adoption study aimed to assess the current neuroimaging approach used for diagnosing
78 people with suspected dementia in the NHS England. We then explored the views of
79 (neuro)radiologists, neurologists and psychiatrists on the potential benefits and level of acceptance of
80 imaging analysis software in supporting MRI scan analysis. As a technology exemplar for the analysis
81 software, we used the FMRIB software library (FSL) (13). FSL is a software package that includes over
82 300 tools capable of extracting various metrics from MRI scans, making it suitable for addressing this
83 clinical need. The software is available for free for academic and personal use, and is licensed for
84 commercial use. We asked the stakeholders perception of an FSL-based software with the following
85 characteristics: 1) compatible with MRI scans and integrated in picture archiving and communication
86 system (PACS); 2) automatically provides quantitative measurements of the volume of cerebral
87 structures currently being measured as part of the dementia assessment (mainly global atrophy,
88 hippocampal atrophy, and white matter hyperintensities); 3) displays data against healthy controls
89 matched for age and sex and expressed as percentile of the normative reference population; 4) generates
90 a quantitative report, prepopulated with hospital number sets, age, date of birth, date of scan and
91 measurements for cerebral structures measured in clinical diagnosis and assessment of dementia.

92 **Material and methods**

93 The Health Innovations Oxford and Thames Valley and Wellcome Centre for Integrative Neuroimaging
94 (the developers of FSL) sought to explore how an imaging analysis software tool could support
95 dementia diagnosis in routine NHS clinical practice.

96 The Lean Assessment Process methodology (14) is used to align evidence generation with available
97 resources at an early stage to explore the unmet clinical needs and the potential barriers to adoption of
98 a new product. The methodology assesses the feasibility of implementing a technology in a care
99 pathway using a preliminary assessment of design, value, and evidence reliability (15). LAP was used
100 to evaluate how the FSL-based software capability and design aligned with the unmet needs in the
101 current dementia diagnosis pathway as well as to identify any potential barrier to its adoption in a
102 clinical setting by engaging with key stakeholders early on in the product development process. Briefly,
103 the dementia diagnosis care pathway was mapped using published guidelines. Ten key stakeholders to
104 interview were identified through both literature review and recommendations. All interviewees were
105 healthcare professionals working in relevant roles within the dementia care pathway across 8 different
106 NHS Trusts in England and included neuroradiologists, general radiologists, FGD-PET radiologists,
107 neurologists and Old Age psychiatrists working in memory clinics. Documents describing the
108 technology were circulated to stakeholders prior to engaging with them. Questionnaires used during the
109 interview contained both qualitative questions on the current landscape and current clinical practices,
110 quantitative product perception questions using a 7-point scale as well as human factor tools adapted
111 from the perceived usefulness questionnaire (16), the stakeholders questionnaire (17) and the net
112 promoter score ((18), which predicts market potential. Qualitative and quantitative data were
113 thematically analysed to build an understanding of the technology acceptability, perceived usefulness
114 and likelihood of its adoption by stakeholders. Moreover, user preferences, stakeholder acceptance,
115 product design and potential barriers of its adoption in the NHS in England were evaluated to further
116 refine the value proposition.

117 **Results**

118 **Views on the current landscape**

119 NICE guidelines were largely followed by stakeholders. The current neuroimaging referral pathway is
120 summarised in Fig 1.

121

122 **Fig 1. Current pathway for the diagnosis of people with suspected dementia in the NHS England**
123 **(NICE guidelines [NG97] Dementia: assessment, management and support for people living with**
124 **dementia and their carers).** Legend: CT: computed tomography, MRI: Magnetic Resonance Imaging,
125 FDG-PET: fluorodeoxyglucose-positron emission tomography-CT, SPECT : single-photon emission
126 CT, CSF: Cerebrospinal fluid, P-tau: phosphorylated-tau, A β : β -amyloid, pTau: phosphorylated tau,
127 ESNR: European Society of Neuroradiology.

128

129 It was recognised by stakeholders that the number of patients referred for neuroimaging is variable
130 across Trusts and clinicians. Most Trusts have a cut-off age to determine whether a patient should be
131 seen by the cognitive neurology team (younger patients) or by an Old Age psychiatrist (older patients).
132 Patients referred to neuroimaging through neurology would all receive an MRI, as the clinicians will be
133 looking for potentially subtle and harder to detect changes in the hippocampus. For psychiatry referrals,
134 CT was predominantly used to rule out alternative causes of cognitive impairment, and is well tolerated
135 in older adults. The level of agreement amongst stakeholders on whether MRI is better than CT in the
136 dementia diagnosis pathway was 88.6%, with clinicians commenting that although the pattern of
137 atrophy or the degree of small vessel disease can be seen on CT, it is “*not as good as what you can*
138 *assess with the MRI*”. However, access to MR scanners was limited.

139 Establishing the diagnosis lies with the referring clinicians with the support of neuroimaging. In some
140 cases, further imaging assessments are required (Fig 1). However, in practice, this concerns a very small
141 number of patients, judiciously selected, as to not overwhelm the radiology services which was

142 commented upon as being “*exceptionally limited and often available off-site in another larger regional*
143 *hospital*”.

144 When discussing reporting time, radiologists mentioned that it would take them about 10-15 minutes to
145 review a scan. Neurologists explained that they typically receive the report back from radiology within
146 a few days, whereas for psychiatrists, turnaround times varied across Trusts, ranging from around 2
147 weeks, up to 6-12 weeks, with up to 3 months from the point of decision to refer to a scan to the person
148 coming back to the clinic. The delay was not necessarily due to radiology, but also to the difficulty of
149 finding an available scanner to perform imaging or a time slot at the memory clinic for reviewing the
150 patient. In the psychiatrists’ opinion, the main adverse effect of the delay related to the fact that patients
151 were anxious to receive a diagnosis but that the delay did not really affect patients’ management as
152 current treatment options for dementia are limited. Stakeholders also mentioned that reporting was
153 sometimes outsourced to external radiologists to decrease delays when the capacity of Trust’s radiology
154 services was limited.

155 Clinicians would provide the radiology department with a short clinical history of the patient,
156 performance on cognitive assessments and the suspected patient’s diagnosis on the referral letter.
157 Radiologists commented that they find it particularly helpful when a good clinical history is provided.
158 For example, the presence of “*word finding difficulties and aphasia*”, or of “*parkinsonian aspects*
159 *associated with hallucinations potentially indicative of Lewy bodies dementia*” would guide them.
160 Radiologists commented that conversely, referrals with requests such as “*please, is there hippocampal*
161 *atrophy*” or “*memory loss*” without any details were found particularly unhelpful.

162 Most of the radiologists used their own reporting templates that they would manually populate with
163 measurements and scores. Vascular burden and microbleeds were assessed before measuring the pattern
164 of atrophy. The decision to assess specific areas would be guided by the referral letter. Some of the
165 cerebral regions assessed by the radiologists interviewed included medial temporal areas, cingulate
166 region, the dorsal regions, convexity of the palate, frontal lobes, cerebellum, mamillary bodies, corpus
167 callosum and brain stem. (Neuro)radiologists would sometimes provide quantitative assessments using

168 visual rating scales or a description of severity. Neuroradiologists mentioned reporting MTA scores,
169 ERICA scores, KOEDAM scores, vascular burden as mild, moderate, severe and FAZEKAS scores.

170 Unlike the neurologists, none of the psychiatrists interviewed had access to the scan images, so they
171 would rely purely on the radiologists' reports. All stakeholders emphasised that neuroimaging was part
172 of the diagnostic assessment but not a standalone diagnostic tool. Overall, the content and quality of
173 reports that clinicians received from radiology were hugely variable.

174 Stakeholders agreed on the need for training and better-quality reporting of MRI scans in dementia
175 diagnosis. The level of agreement on the need for software to support the analysis of volumetric MRI
176 scan and provide quantitative data was 80.7%.

177 **Perception of the technology**

178 Table 1 summarises the answers of the stakeholders to questions about their individual perspective
179 (level of agreement) and the perceived usefulness of the technology. 83.3% of stakeholders stated they
180 would promote the technology in future. When asked about the potential added value, impact on clinical
181 practice and key functionalities of the technology the stakeholders discussed several aspects.

182

183 **Table 1.** Stakeholder's average level of agreement and perceived usefulness of the proposed analysis
184 software based on FSL.

Individual perspective - level of agreement

1	MRI is better than CT in the diagnosis pathway of people with suspected dementia.	88.6%
2	There is an unmet need for an analysis software to support the analysis of MRI scans and to provide quantitative data.	80.7%
3	Quantitative data in MRI reporting can increase diagnostic specificity, accuracy and confidence while decreasing inter-rater variability.	88.6%

4	Quantitative data from MRI can help with differential diagnosis which in turn, can help better inform patient's care needs.	76.4%
5	Quantitative data from MRI can be useful with early diagnosis in a subpopulation of patients with suspected dementia.	81.4%
6	A software like the one proposed, that automatically produces volumetric MRI measurements and generates a prepopulated report, can save radiologists/clinicians time and improve workflow.	77.1%
7	In view of the research effort to develop drugs for dementia, quantitative data from MRI would be useful in clinical practice when disease-modifying drugs become available.	81.4%
8	Do you agree that there are potential barriers to the adoption of the proposed software for clinical use?	78.6%

Perceived usefulness

1	Improve quality of work	75.0%
2	Give greater control of work	63.4%
3	Enable to accomplish tasks more quickly	57.1%
4	Support critical aspects of the job	72.3%
5	Increase productivity	59.8%
6	Improve job performance	73.2%
7	Allow to accomplish more work	58.9%
8	Enhance effectiveness on the job	73.2%
9	Make job easier to do	66.1%
10	Overall, this product is useful	80.4%

185

186 Increased confidence. Both radiologists and clinicians mentioned increased confidence in diagnosis as
 187 the main added value. The level of agreement amongst stakeholders on the capability of quantitative
 188 MRI reports to increase diagnostic specificity, accuracy and confidence while decreasing inter-rater
 189 variability was 88.6%. Having quantitative data would give them greater confidence in the MRI findings
 190 and potentially reduce the need for further FDG-PET scans, which are more expensive and with less
 191 capacity. However, some neuroradiologists raised concerns about people with little experience of

192 dementia imaging using the sort of software that might give a sense of “false reassurance to a general
193 radiologist”.

194 *“Then you can very, very quickly say: okay the pattern in this convincingly matches the clinical input.
195 Nothing else to be said. You move on. So it would be straight forward for the patient, straight forward,
196 for the clinician, straight forward for radiologist. So you have less patients in the limbo they are until
197 you reach a diagnosis, which sometimes is very time consuming.”* - Consultant neuroradiologist

198 *“I think a neuroradiologist would know what is going on but if you don’t have a neuro background,
199 and it is just purely imaging, that is a different conversation”.* - Consultant neuroradiologist

200 Support delivery of disease modifying therapies (DMTs). The level of agreement on whether
201 quantitative MRI would be useful to clinicians when DMTs become available was 81.4%.

202 Some stakeholders believed MRI in this pathway will be used to look for dementia drugs
203 contraindications because of the risk of bleeds associated with their use. Others felt that MRI will be
204 used to monitor the effects of these drugs on disease progression and in that context, quantitative MRI
205 will provide valuable data. However, stakeholders also commented that the whole dementia diagnosis
206 pathway is likely to change with the arrival of dementia-modifying drugs and that eligibility criteria for
207 these expensive treatments will be based on fluid biomarkers such as serum amyloid levels or amyloid-
208 PET rather than MRI. In some stakeholders’ views, the future of MRI in the dementia pathway will not
209 be for diagnostic purposes as fluid biomarkers will likely have higher predictive value, lower cost and
210 higher accessibility than MRI. Instead, they see MRI being used for safety monitoring and for
211 determining which treatments patients should receive.

212 *“I would say vital. So when we get to dementia modifying drugs, there will be a pathway. I think the
213 pathway will involve both neuroimaging, potentially blood biomarkers for negatives and then only in
214 the people where you’ve really done everything to rule out other causes, do you do the lumbar
215 puncture.”* - Consultant psychiatrist

216 “...[diagnostic] criteria is going to be amyloid status rather than any other parameters, so it would be
217 amyloid-PET or hopefully serum levels of amyloid and other relevant actors” - Consultant psychiatrist

218 "...the future of MR imaging in dementia diagnosis is not going to be diagnostic. It's going to be safety
219 for treatment ... The diagnosis will be done in a different way.” - Consultant neurologist

220 Comparison with a control population. One of the main perceived benefits of such a software tool was
221 that it would provide comparison of the patient’s measurement with those of a normative population
222 matched for age and sex. All stakeholders commented that this information would be very valuable both
223 in a younger population of patients where the volume of cerebral structures such as the parietal cortex
224 is highly variable, as well as in the older population where the rate of atrophy varies significantly
225 between individuals and does not necessarily correlate with cognitive impairments. However,
226 stakeholders were keen to be provided with information on the composition of the control population
227 used to display the results (and train the AI if applicable). Questions asked pertained to how many
228 control scans were going to be used (to judge the variance of the results), where the control population
229 came from (to make sure it is representative of the population where the tool is being deployed), and if
230 an amyloid scan has been performed on these healthy individuals (to check whether they could be in a
231 pre-dementia state). Uncertainty around the control population was also the main reason for loss of
232 confidence in commercially available software that had been tried by some stakeholders.

233 Assessment of microbleeds and vascular pathology. Microbleeds were seen as extremely important to
234 consider. Although their assessment is not part of the current dementia diagnosis, stakeholders felt that
235 they will need to be measured more accurately by neuroradiologists when new dementia drugs are
236 available. Quantification of microbleeds and vascular change would inform on what the bleeding risk
237 would be for disease management and informing treatment.

238 “At the moment, we don’t use and I don’t need it, but I can see that a rapid automated assessment to
239 determine the risk of bleeds and that would become of particular value when we come to the treatment
240 for the amyloid which is not very far away.” – Consultant neuroradiologist

241 Other added values of the technology for stakeholders were the possibility to detect subtle changes,
242 save time saving, and differentiate age related changes from pathological changes. Other key
243 functionalities mentioned to be added to the software were comparison of multiple scans, and
244 segmentation of multiple brain structures to assess atrophy patterns and other abnormalities.

245 **Barriers to adoption**

246 Stakeholders recognised the likelihood of barriers to the adoption of a software tool like the proposed
247 one in the clinical setting, with 78.6% agreement to the question: "Do you agree that there are potential
248 barriers to the adoption of the proposed software for clinical use?"

249 Key barriers to adoption of such a software tool were the limited access to MRI scanners, in particular
250 3 Tesla, in NHS services and therefore CT is widely relied on in the dementia care pathway. The
251 psychiatrists interviewed estimated the ratio to be 2/3 CT and 1/3 MR in one trust and 95% of CT in
252 the other. The demand for MRI scans for eligibility screening and safety monitoring in the dementia
253 care pathway will increase in the coming years when DMTs come to market. However, in the UK there
254 are currently 8.6 MRI scanners per million people compared to 38 and 35.3 in the US and Germany
255 respectively (19).

256 *"MRI access is an issue. We are not really encouraged to ask for MRI scans. So if I asked for CT scan,*
257 *they're pretty much will always say yes; If I ask for an MRI scan, they'll triage it much more carefully."*-
258 Consultant Psychiatrist

259 *"Because of various things, as we've discussed, about capacity, availability, some patients can't have*
260 *an MRI. I think in an ideal world, you would want everyone to have an MRI, but we don't live in an*
261 *ideal world."*- Head and Neck Consultant Radiologist

262 Additional barriers identified by stakeholders were related to integration in the clinical workflow (IT
263 and time requirements); structural issues within the NHS making it hard for innovations to be adopted;
264 potential issues with information governance; managers' attitudes towards innovation; and the cost of

265 the technology. Stakeholders explained that to introduce an innovation into the department, one needs
266 to write a business case to demonstrate that the innovation will be cost-effective. For example, “to
267 demonstrate that saving time on reporting scan would result in xx extra scan reported, equating to ‘x’
268 amount of savings”. This business case would therefore be highly dependent on the number of dementia
269 scans processed in the radiology department. If dementia scans are not the bulk of their activity,
270 radiologists will have to demonstrate that the software could be used for imaging of other pathologies,
271 such as multiple sclerosis. However, stakeholders also thought that although cost would be an issue,
272 they were confident that there were ways around it, for example using champions to promote the
273 analysis software.

274 **Discussion**

275 The current study aimed at exploring the perceived usefulness and level of acceptance of a brain
276 imaging software tool, using FSL as a technology exemplar for the analysis software, in providing
277 quantitative reporting of MRI scans in the dementia diagnosis pathway. To gain a broad view of
278 potential barriers to adoption in clinical practice in NHS England, we interviewed stakeholders who
279 worked in 8 different Trusts across England in relevant roles in the dementia pathway.

280 Although imaging is an integral part of the dementia pathway in most cases, the choice of CT vs MRI
281 is made mainly based on the referring service (CT for psychiatry, MRI for neurology) and access to
282 MRI scanners. Reporting time is heterogeneous for psychiatry and neurology, and the content of reports
283 is variable. Reports usually contain common elements, but the level of detail provided, as well as the
284 use of visual rating scales is not consistent. Despite clinicians and radiologists agreeing on the
285 usefulness of structured reports, there was no consensus on a common template. This is in line with
286 what has been recently reported by the European Society of Radiology: while in many countries national
287 radiological societies have launched initiatives to further promote structured reporting, cross-
288 institutional applications of report templates (e.g., for registries or research) and incentives for usage of
289 structured reporting (monetary or structural) are lacking (20). In addition, the specificity in the referral
290 question, the specialty of the radiologist/neuroradiologist, and specialty of the referring clinician seem

291 to contribute to the heterogeneity in content as well as to the level of trust in the report. Importantly,
292 while neurologists have access to the images and often personally review them alongside the radiology
293 report, psychiatrists typically only have access to the report and not the images.

294 In this context, stakeholders agreed that there was a need for software to provide volumetric
295 quantification of brain MRI and for better reporting in the dementia diagnosis pathway. With the
296 shortage of radiology workforce (29% in 2022 (21)) and the predicted increased number of referrals for
297 dementia diagnosis scans, the proposed software was seen as a useful radiology support tool for
298 analysing brain scans. For radiologists, although the software was perceived as not saving time per se,
299 they would expect it to increase their diagnostic confidence by allowing patients to be compared to
300 normative data. For clinicians, the creation of a structured report collating all the information needed to
301 make a diagnosis was also seen as helpful. More importantly, it could reduce the variability between
302 reporters and decrease the subjectivity of the report, a point seen as important by clinicians in the context
303 of shortage of neuroradiologists. If the proposed FSL-based software was coupled with additional
304 features such as measuring other cerebral structures, comparing scans and microbleeds measurement,
305 this software could serve several purposes within the dementia pathway: as a diagnostic tool to better
306 identify the subtype of dementia and reduce the need for further investigation; as a monitoring tool to
307 measure subtle changes and evaluate disease progression or the effect of disease-modifying treatments;
308 and/or as a tool to identify risk of bleeding, particularly relevant in view of the safety monitoring
309 required for dementia drugs soon to be available.

310 When discussing their confidence in the outputs of the software, stakeholders explained that they would
311 have to be provided with information on the software's sensitivity and specificity. Information on the
312 control population used would be useful to reassure users that it is representative of the local population
313 both in its diversity and across all ages. Stakeholders also mentioned the important balance between the
314 software increasing confidence and the risk of creating a "false sense of reassurance" that the
315 measurements are adequate if they lack the knowledge to quality-control the findings of the software.

316 One of the main barriers to adoption of such software was the limited access to MRI scanners, and
317 therefore the fact that CT is widely relied on in the dementia care pathway. Other barriers mentioned
318 by all stakeholders were the cost and the need to demonstrate that the software would be a cost-effective
319 tool for brain reporting. Stakeholders were unsure whether using quantitative MRI could save them
320 time or reduce the need for further investigations. Some stakeholders were of the view that the role of
321 quantitative MRI in the future dementia diagnosis pathway would only be to assess the risk of bleeds,
322 while biofluid measurements will probably become the mainstream diagnostic biomarkers for early
323 dementia. Showing that the software could be useful in other pathways, and finding champions to
324 promote it, were proposed by stakeholders as potential solutions to convince NHS managers to acquire
325 it.

326 While covering a broad complement of stakeholders in relevant roles in the dementia diagnosis
327 pathway, across 8 different NHS trusts, the stakeholder sample size was small (n=10) which is a
328 limitation of this study.

329 Altogether, this barrier to adoption study using LAP methodology reported that stakeholders were very
330 positive about the potential usefulness of brain analysis software tool in the dementia diagnosis
331 pathway, as reflected by the overall usefulness score of 80.4%, a score even greater for radiologists as
332 primary users of the software.

333 This study highlighted several future directions towards the adoption of brain imaging software to
334 support dementia diagnosis in the NHS England. Regarding the software technical requirements,
335 specific measures (microbleeds, segmentation of multiple structures) and functionalities (representative
336 control population, comparison of scans over time) were mentioned as important to include to meet
337 clinical needs. These improvements should be supported with technical validation studies to improve
338 confidence in the software. A clinical evaluation study involving clinical end-users would test the value
339 of the software compared to a standard reading. This could include measuring the reporting time and
340 accuracy, assessing confidence in diagnosis, as well as gathering feedback around the usability and
341 acceptability of the software. An integration test in a clinical setting would enable assessing the impact

342 of the software in the clinical workflow. Joint clinical-research facilities like the Oxford Brain Health
343 Clinic (22) provide an ideal translational interface to test the software on data from real-world clinical
344 populations in a research setting, while building evidence for further adoption. Finally, a real-world
345 health economic evaluation will be required to determine the cost-effectiveness and to capture the
346 clinical effectiveness as well as gathering further clinical evidence.

347

348 **References**

- 349 1. Carnall Farrar AsS. The economic impact of dementia [Available from:
350 [https://www.carnallfarrar.com/wp-content/uploads/2024/06/The-economic-impact-of-dementia-
352 CF.pdf](https://www.carnallfarrar.com/wp-content/uploads/2024/06/The-economic-impact-of-dementia-
351 CF.pdf).
353 2. Wittenberg R, Hu B, Barraza-Araiza L, Rehill A. Projections of older people living with
354 dementia and costs of dementia care in the United Kingdom, 2019–2040. Care Policy and Evaluation
355 Centre Working Paper 5, London School of Economics and Political Science; 2019.
356 3. NICE. Dementia: assessment, management and support for people living with dementia and
357 their carers. NICE guideline [NG97]2018.
358 4. van Straaten EC, Scheltens P, Barkhof F. MRI and CT in the diagnosis of vascular dementia.
359 J Neurol Sci. 2004;226(1-2):9-12.
360 5. Harper L, Barkhof F, Fox NC, Schott JM. Using visual rating to diagnose dementia: a critical
361 evaluation of MRI atrophy scales. Journal of neurology, neurosurgery, and psychiatry.
362 2015;86(11):1225-33.
363 6. Vernooij MW, Pizzini FB, Schmidt R, Smits M, Yousry TA, Bargallo N, et al. Dementia
364 imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR
365 working group. Neuroradiology. 2019;61(6):633-42.
366 7. Psychiatrists RCo. National Audit of Dementia: Memory Assessment Services Spotlight
367 Audit 2021. 2022.
368 8. Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Jr., Poussaint TY, et al.
369 Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection
370 and Reporting Recommendations for Clinical Practice. AJNR American journal of neuroradiology.
371 2022;43(9):E19-E35.
372 9. Pemberton HG, Zaki LAM, Goodkin O, Das RK, Steketee RME, Barkhof F, et al. Technical
373 and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a
systematic review. Neuroradiology. 2021;63(11):1773-89.

- 374 10. Pemberton HG, Goodkin O, Prados F, Das RK, Vos SB, Moggridge J, et al. Automated
375 quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater,
376 clinical accuracy study. *Eur Radiol*. 2021.
- 377 11. Bosco P, Redolfi A, Bocchetta M, Ferrari C, Mega A, Galluzzi S, et al. The impact of
378 automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's
379 disease: A European Alzheimer's Disease Consortium study. *Alzheimer's & dementia : the journal of*
380 *the Alzheimer's Association*. 2017;13(9):1013-23.
- 381 12. Goodkin O, Pemberton H, Vos SB, Prados F, Sudre CH, Moggridge J, et al. The quantitative
382 neuroradiology initiative framework: application to dementia. *Br J Radiol*. 2019;92(1101):20190365.
- 383 13. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL. *NeuroImage*.
384 2012;62(2):782-90.
- 385 14. Bajre MT, A; Stainthorpe, A; Hart, J. Results from an Early Economic Evaluation of the use
386 of A Novel Point of Care Device for Diagnosis of Suspected Acute Coronary Syndrome Patient
387 Within an Emergency Department in the National Health Service in England. *Cardiology and*
388 *Cardiovascular Medicine*. 2021;5:623-37.
- 389 15. Bajre M, Moawad M, Shumbayawonda E, Carolan JE, Hart J, Culver E, et al. LiverMultiScan
390 as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in
391 England: an economic evaluation. *BMJ Open*. 2022;12(9):e058999.
- 392 16. Davis FD. User Acceptance of Information Technology: System Characteristics, User
393 Perceptions and Behavioral Impacts. *Int J Man Mach Stud*. 1993;38:475-87.
- 394 17. World Health Organization. Regional Office for the Western P. Health service planning and
395 policy-making : a toolkit for nurses and midwives - Module 2: Stakeholder analysis and networks.
396 Manila: WHO Regional Office for the Western Pacific; 2005.
- 397 18. Reichheld FF. The one number you need to grow. *Harv Bus Rev*. 2003;81(12):46-54, 124.
- 398 19. OECD. Number of magnetic resonance imaging (MRI) units in selected countries as of 2021
399 (per million population). Statista Inc.; 2023.
- 400 20. European Society of R. ESR paper on structured reporting in radiology-update 2023. *Insights*
401 *Imaging*. 2023;14(1):199.

- 402 21. Radiologists TRCo. Clinical Radiology Workforce Census 2022. 2023.
- 403 22. O'Donoghue MC, Blane J, Gillis G, Mitchell R, Lindsay K, Semple J, et al. Oxford brain
404 health clinic: protocol and research database. *BMJ Open*. 2023;13(8):e067808.
- 405

Current pathway for the diagnosis of people living with dementia

Referral received by General Practitioner. Reversible causes of cognitive decline (including delirium, depression, sensory impairment [such as sight or hearing loss] or cognitive impairment from medicines associated with increased anticholinergic burden) have been investigated **and** dementia is still suspected

Diagnosis in specialist dementia diagnostic services (typically neurology services for younger patients and psychiatry services for older patients)

Diagnose a dementia subtype (if possible) if initial specialist assessment (including an appropriate neurological examination and cognitive testing) confirms cognitive decline and reversible causes have been ruled out.

If Alzheimer's disease is suspected, include a test of verbal episodic memory in the assessment

Consider neuropsychological testing
Offer structural imaging (CT or MRI)

Qualitative MRI reporting

Further appointment/assessments to increase diagnosis confidence potentially needed

Only consider further tests if it would help to diagnose a dementia subtype and knowing more about the dementia subtype would change management

If the diagnosis is uncertain and Alzheimer's disease is suspected,

consider either:

FDG-PET or perfusion SPECT if FDG-PET is unavailable **or** examining CSF for either total tau or total tau and p-Tau 181 **and** either A β 1-42 or A β 1-42 and A β 1-40

If the diagnosis is uncertain and dementia with Lewy bodies is suspected,

- use ^{123}I -FP-CIT SPECT
- If ^{123}I -FP-CIT SPECT is unavailable, consider ^{123}I -MIBG cardiac scintigraphy

If the diagnosis is uncertain and frontotemporal dementia is suspected,

- use either:
- FDG-PET **or**
 - perfusion SPECT

If the dementia subtype is uncertain and vascular dementia is suspected,

- use MRI.
- If MRI is unavailable or contraindicated, use CT

Appropriate post-diagnosis care plan and interventions put in place